drugset / Trial / NCT00230334
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the trial is to determine the safety and efficacy of Gleevec" in idiopathic hypereosinophilic syndrome (HES) and to characterize the molecular basis for the therapeutic benefit of Gleevec" in HES.
Timeline
- Start
- 2003-06-12
- Primary completion
- 2006-12-29
- Completion
- 2007-05
Outcome
Outcome not reported
Stopped (Enrollment): “terminated by PI due to insufficient accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | — | — |